Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the company. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $20.17.

A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Jefferies Group LLC cut their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Raymond James Financial, Inc. cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their target price for the company from $21.00 to $18.00 in a research note on Tuesday, March 14th. Piper Jaffray Companies cut their target price on shares of Amphastar Pharmaceuticals from $22.00 to $20.00 and set an “overweight” rating for the company in a research note on Tuesday, March 14th. Finally, BMO Capital Markets cut their target price on shares of Amphastar Pharmaceuticals from $18.00 to $16.00 and set a “market perform” rating for the company in a research note on Tuesday, March 14th.

In other news, Director Richard K. Prins sold 7,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, May 11th. The shares were sold at an average price of $15.43, for a total value of $115,725.00. Following the completion of the transaction, the director now owns 30,500 shares in the company, valued at $470,615. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 29.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. First Quadrant L P CA bought a new position in Amphastar Pharmaceuticals during the third quarter valued at $842,000. Bank of Montreal Can boosted its position in Amphastar Pharmaceuticals by 358.7% in the third quarter. Bank of Montreal Can now owns 83,120 shares of the company’s stock valued at $1,577,000 after buying an additional 65,000 shares during the period. Boston Advisors LLC bought a new position in Amphastar Pharmaceuticals during the third quarter valued at $302,000. Kalmar Investments Inc. DE boosted its position in Amphastar Pharmaceuticals by 20.7% in the third quarter. Kalmar Investments Inc. DE now owns 254,418 shares of the company’s stock valued at $4,826,000 after buying an additional 43,703 shares during the period. Finally, Chicago Equity Partners LLC bought a new position in Amphastar Pharmaceuticals during the third quarter valued at $1,375,000. Hedge funds and other institutional investors own 49.09% of the company’s stock.

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 15.45 on Monday. The stock’s 50 day moving average price is $14.97 and its 200-day moving average price is $16.80. The firm has a market capitalization of $706.64 million, a PE ratio of 81.32 and a beta of 1.74. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Monday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by $0.03. The company had revenue of $56.67 million for the quarter, compared to analyst estimates of $63.74 million. Amphastar Pharmaceuticals had a net margin of 7.75% and a return on equity of 6.79%. The firm’s revenue for the quarter was down 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.12 earnings per share. On average, equities analysts anticipate that Amphastar Pharmaceuticals will post $0.40 earnings per share for the current fiscal year.

WARNING: “Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of “Buy” from Brokerages” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://sportsperspectives.com/2017/05/20/amphastar-pharmaceuticals-inc-amph-receives-20-33-average-target-price-from-analysts-updated-updated-updated.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

12 Month Chart for NASDAQ:AMPH

Receive News & Ratings for Amphastar Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply